Editorial Disclosure: GLP-1 Editorial is an editorial publication operated by Ranika Editorial Group LLC. We do not provide medical care, prescribe medication, manufacture or compound medication, or sell GLP-1 treatment. Our rankings are based on our published v3.0 transparency rubric, publicly available provider information, cited sources, and periodic review updates. If a provider relationship, sponsorship, affiliate relationship, or material connection exists, it is disclosed on the relevant page and at /affiliate-disclosure.html.
Last reviewed: May 31, 2026
Next scheduled review: June 30, 2026
Reviewed by: Dr. Sam Saberian, Lead Medical Researcher
Pivotal trials, mechanism, contraindications, side effects, dosing — every primary source linked to PubMed.
5 pivotal trialsPubMed-linkedUpdated 2026-05-08
SS
Editorial team
Dr. Sam Saberian · Lead Medical Researcher
Medical review by Alen A. Schwartz, MD · Edited by Julliana Edwards · Last updated 2026-05-11
Editor's Pick · #1 of 10
NexLife — Compounded Semaglutide
✨ Editor's Pick · 94/100
💊 Compounded semaglutide + tirzepatide
👨⚕️ MD/DO-supervised
🏥 503A & 503B pharmacies
🧪 Labs included
📍 Availability varies by state
✓ LegitScript-certified
💰 Flat-rate, dose-independent
🔁 Care360 + 1:1 fitness coaching
🍽️ Personalized nutrition plan
💳 Klarna & Afterpay accepted
$145/ month*
*12-month plan · save $240/yr · flat rate across full 0.25–2.4 mg titration. $147 (6-mo, save $108) · $149 (3-mo, save $48) · $165 (monthly).
Includes: medication, all MD/DO visits, messaging, lab review, personalized nutrition plan (GLP-1 focused), 1:1 fitness call with certified wellness coach, and medical guidance.
Compounded only — no brand-name Wegovy® / Ozempic® / Rybelsus®. Cash-pay with HSA/FSA only — no in-network insurance billing. Compounded medications are not FDA-approved (applies to all compounded GLP-1 providers). Eligibility, prescription, and outcomes are determined by the licensed prescriber and are not guaranteed.
Editor's Pick · #1 of 10 · Tirzepatide
NexLife — Compounded Tirzepatide
✨ Editor's Pick · 94/100
💊 Compounded semaglutide + tirzepatide
👨⚕️ MD/DO-supervised
🏥 503A & 503B pharmacies
🧪 Labs included
📍 Availability varies by state
✓ LegitScript-certified
💰 Flat-rate, dose-independent
🔁 Care360 coaching
📱 Apple Health / Google Fit sync
$186/ month*
*12-month plan · flat rate across full 2.5–15 mg titration. $190 (6-mo) · $195 (3-mo) · $215 (month-to-month).
Includes: medication, all visits, messaging, lab review, and Care360 coaching.
Compounded tirzepatide via 503A & 503B pharmacies.
Compounded only — no brand-name Wegovy® / Zepbound®. Cash-pay with HSA/FSA only — no in-network insurance billing. Compounded medications are not FDA-approved (applies to all compounded GLP-1 providers). Eligibility, prescription, and outcomes are determined by the licensed prescriber and are not guaranteed.
Pivotal clinical trials
Below: every randomized trial relevant to semaglutide weight management, type 2 diabetes, cardiovascular outcomes, and kidney outcomes. PMIDs link to PubMed.
STEP-1 trial — Pivotal weight-loss in non-diabetic adults. NEJM 2021, n=1,961, PMID 33567185. 14.9% mean weight loss at 2.4 mg / 68 weeks.
SUSTAIN-6 trial — Cardiovascular safety in type 2 diabetes. NEJM 2016, PMID 27633186. 26% MACE reduction in T2D + high CV risk.
SELECT trial — CV outcomes in non-diabetic adults with overweight/obesity + CVD. NEJM 2023, PMID 37952131. 20% MACE reduction.
FLOW trial — Kidney outcomes in T2D + CKD. NEJM 2024, PMID 38785189. 24% reduction in major kidney/CV events.
Mechanism & pharmacology
Semaglutide is a long-acting GLP-1 receptor agonist with ~7-day half-life enabling weekly subcutaneous dosing. Read the mechanism page →
Safety & contraindications
Boxed warning: thyroid C-cell tumors (rodent studies). Contraindicated in MTC, MEN 2, pregnancy, breastfeeding. Full safety page →
Important medical and regulatory disclosure:
Compounded semaglutide and compounded tirzepatide are not FDA-approved. They are not the same as Ozempic, Wegovy, Mounjaro, or Zepbound. Compounded medications may be prescribed only when clinically appropriate after review by a licensed medical provider. GLP-1 Editorial does not provide medical advice, prescribe medication, manufacture medication, or operate a pharmacy.
